(Q54681050)

2 June 2018

title

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. (English)

1 reference

2 June 2018

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

patient

0 references

angiogenesis inhibitor

1 reference

3

1 reference

2 June 2018

author name string

Fumihiko Kanai

1

1 reference

2 June 2018

Haruhiko Yoshida

2

1 reference

2 June 2018

Shinpei Sato

4

1 reference

2 June 2018

Takao Kawabe

5

1 reference

2 June 2018

Shuntaro Obi

6

1 reference

2 June 2018

Yuji Kondo

7

1 reference

2 June 2018

Makoto Taniguchi

8

1 reference

2 June 2018

Kazumi Tagawa

9

1 reference

2 June 2018

Masafumi Ikeda

10

1 reference

2 June 2018

Chigusa Morizane

11

1 reference

2 June 2018

Takuji Okusaka

12

1 reference

2 June 2018

Hitoshi Arioka

13

1 reference

2 June 2018

Shuichiro Shiina

14

1 reference

2 June 2018

Masao Omata

15

1 reference

2 June 2018

publication date

1 February 2011

1 reference

2 June 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

2 June 2018

volume

67

1 reference

2 June 2018

issue

2

1 reference

2 June 2018

page(s)

315-324

1 reference

2 June 2018

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Novel advancements in the management of hepatocellular carcinoma in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Opportunities for targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1320-2

10.1007/S00280-010-1320-2

21 January 2018

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018